List of works - Rachel Brough

Resistance to therapy caused by intragenic deletion in BRCA2

scientific article

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

scientific article

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

scientific article published on 03 April 2008

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

scientific article

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

scientific article

Functional viability profiles of breast cancer

scientific article

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

scientific article

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

scientific article published on 13 December 2016

Searching for synthetic lethality in cancer

scientific article published on 20 January 2011

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

scientific article published on 10 May 2018

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

scientific article published on 2 March 2016

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

scientific article

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers

scientific article

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

scientific article

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer

scientific article

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

scientific article

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

scientific article

Functional analysis of Drosophila melanogaster BRCA2 in DNA repair

scientific article published on 5 September 2007

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

scientific article published on 15 June 2017

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

scientific article

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

scientific article

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells

scientific article

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

scientific article published on 20 April 2017

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

scientific article published on 18 April 2016

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

scientific article published in PLoS ONE

List of works by Rachel Brough

Resistance to therapy caused by intragenic deletion in BRCA2

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Functional viability profiles of breast cancer

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Searching for synthetic lethality in cancer

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Functional analysis of Drosophila melanogaster BRCA2 in DNA repair

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours